(Photo illustration by Cheng Xin/Getty Images)Getty ImagesDeal OverviewAccording to media publications on July 11, 2025, The Kraft Heinz Company (NASDAQ: KHC, $27.58, Market Capitalization: $32.64 billion), a leading global packaged food company, is contemplating spinning-off its grocery business while retaining its high growth condiments and sauces segment. As per market estimates, the spin-off entity would command a valuation $20 billion, on favorable turnaround of business prospects.The Kraft Heinz Price ...

RT Oscar (@oscar_shibainu)Real-World Impact through https://t.co/V0QrUZMR4W @k9_rescue 🐾🦮🍖This is a huge opportunity to feed stray dogs for just 50 cents per meal and leave your legacy and good karma echoing forever on-chain!Oscar’s charity portal, https://t.co/V0QrUZMR4W, is already live and fully integrated with @ShibariumNet. It allows instant, transparent, and verifiable on-chain donations, providing meals to stray dogs worldwide at a cost of just $0.50 per meal.To date, over 200 on-chain donations have ...

RT Poloniex Exchange (@Poloniex)🎉 Poloniex 200k $OSCAR Giveaway! 💰1️⃣ Follow @oscar_shibainu & @Poloniex2️⃣ Like, RT & Tag 3 Friends3️⃣ Join TG https://t.co/WHcXBg1eGY4️⃣ Fill up form here https://t.co/SPOHsMHzCU⏰ July 20end🎁 3 winners #Airdrop #Giveaway https://t.co/WIRBVHDbq4 ...

Kraft Heinz Co. KHC is reportedly exploring a significant corporate restructuring, potentially splitting into two distinct entities: a grocery division and a “Taste Elevation” segment focused on sauces and spreads. The potential breakup, if realized, would mark a pivotal moment for the food giant, formed by the high-profile 2015 merger of Kraft and Heinz. While the company has not confirmed the rumors, the move aligns with recent strategic announcements to enhance shareholder value. However, the prospect of ...

What the breakup of Kraft Heinz could mean for ketchup, Oscar Mayer hot dogs and Velveeta https://t.co/DtbhZkIGDB ...

Core Viewpoint - Kraft Heinz is considering a spinoff of a significant portion of its grocery business due to changing consumer preferences towards healthier, less processed foods, which could create a new entity valued at up to $20 billion [1][7]. Company Strategy - The remaining Kraft Heinz entity would focus on sauces and condiments, including well-known brands like Heinz ketchup and Grey Poupon [2]. - Executives believe that separating the two units could enhance overall market value, potentially exceeding the current $31 billion market cap [3]. Financial Performance - Kraft Heinz has struggled to meet expectations since its 2015 merger, with little sales growth and declining profits, resulting in a stock price drop of over 60%, equating to a loss of approximately $57 billion in market value [11][16]. - The company reported around $28 billion in annual revenue at the time of the merger, but by 2019, it faced rising costs and a $15 billion write-down related to its Kraft and Oscar Mayer brands [8][9]. Market Response - Following news of the potential spinoff, Kraft Heinz shares surged nearly 4%, trading around $27 [2]. - The stock has experienced significant volatility, peaking near $96 in early 2017 and recently opening at $26.90, just above its 52-week low [12]. Strategic Considerations - Kraft Heinz is evaluating various strategic transactions to unlock shareholder value, with discussions ongoing but no final decisions made yet [4][14]. - The company has also been exploring the sale of underperforming brands, including Oscar Mayer and Maxwell House, but these efforts have not yet succeeded [13].

Key Takeaways Teleflex completed its 760 million euro acquisition of BIOTRONIK's Vascular Intervention business. The deal expands TFX's interventional access line and supports resorbable scaffold tech development. The acquisition is expected to add $0.10 to TFX's adjusted EPS in year one, with a rising impact thereafter.Teleflex (TFX) recently completed its previously announced acquisition of the majority of BIOTRONIK SE & Co. KG’s Vascular Intervention business. The acquisition significantly expands the ...

Core Point - Kraft Heinz Food Company is recalling nearly 368,000 pounds of Oscar Mayer turkey bacon products due to potential listeria contamination, which can lead to food poisoning [1][4]. Group 1: Recall Details - The recall involves fully cooked turkey bacon produced between April 24 and June 11 [2]. - The affected products were shipped to stores across the US, as well as the British Virgin Islands and Hong Kong [4]. - Specific products include 12-ounce, 36-ounce, and 48-ounce packages of Oscar Mayer Turkey Bacon Original, with various UPC codes and use-by dates ranging from July 18 to September 4 [5]. Group 2: Health Risks - Listeria infections can cause severe illness, particularly in vulnerable populations such as older adults, pregnant women, and individuals with weakened immune systems [7]. - Symptoms of listeria infection include fever, muscle aches, headache, stiff neck, confusion, loss of balance, and convulsions [7]. - The CDC reports that approximately 1,600 people are affected by listeria infections annually, resulting in about 260 deaths [7]. Group 3: Industry Context - Federal officials are revising protocols to prevent listeria infections following several outbreaks, including a notable incident linked to Boar's Head deli meats that resulted in 10 deaths and over 60 illnesses last year [8].

Core Viewpoint - Teleflex Incorporated has successfully completed the acquisition of substantially all of the Vascular Intervention business from BIOTRONIK SE & Co. KG, enhancing its portfolio and global presence in the cath lab and peripheral intervention market [1][3][5]. Acquisition Details - The acquisition was finalized for a cash payment of €760 million, subject to certain adjustments [2]. - The Vascular Intervention business includes a comprehensive portfolio for coronary and peripheral interventions, featuring key products such as the Pantera™ Lux™ Drug-Coated Balloon Catheter and the Orsiro™ Mission Drug Eluting Stent [3][4]. Financial Outlook - The acquired products are expected to generate revenues of €177 million ($204 million) in the second half of 2025, with an anticipated €91 million ($105 million) for the fourth quarter of 2025 [5]. - From 2026 onwards, annual constant currency revenue growth of 6% or better is expected from the acquired products [5][6]. Strategic Implications - The acquisition will allow Teleflex to invest in the clinical trial program for Freesolve™, a sirolimus-eluting Resorbable Metallic Scaffold technology, with plans for a U.S. pivotal study [4]. - The integration of the Vascular Intervention business is anticipated to enhance Teleflex's innovation pipeline and position the company to leverage emerging technologies in the market [3][4].

Hims & Hers Health shares rocketed higher over the last year, rewarding investors.When it comes to healthcare stocks, many investors pay attention to the usual suspects: Eli Lilly, Novo Nordisk, CVS Health, or Johnson & Johnson. These companies have built up enormous brand equity thanks to blockbuster drugs and widely recognized pharmacy management services.With the exception of CVS, whose shares have risen 46% so far this year, none of the other companies have generated robust stock price returns so far in ...